Australia’s largest life sciences private equity company, Brandon Capital, has announced a landmark exit as Novartis moves to acquire its portfolio company Myricx Bio in a deal valued at up to US$1.5 billion, including an upfront cash payment of US$1.1 billion and further milestone payments. …
Brandon Capital secures landmark Novartis acquisition of Myricx Bio
July 6, 2026 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australian Healthcare Associates retains deal to administer the CSO funding pool through 2029
July 7, 2026 - - Latest News -
Brandon Capital secures landmark Novartis acquisition of Myricx Bio
July 6, 2026 - - Latest News -
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech -
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
July 6, 2026 - - Latest News